Lördag 26 April | 16:26:38 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-27 12:00 Kvartalsrapport 2025-Q3
2025-08-28 12:00 Kvartalsrapport 2025-Q2
2025-05-29 12:00 Kvartalsrapport 2025-Q1
2025-05-09 N/A X-dag ordinarie utdelning POLAR 0.00 SEK
2025-05-08 N/A Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2025-02-20 - Extra Bolagsstämma 2024
2024-12-05 - Split POLAR 300:1
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-29 - X-dag ordinarie utdelning POLAR 0.00 SEK
2024-05-28 - Årsstämma
2024-02-23 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-09-08 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-17 - Årsstämma
2023-05-05 - X-dag ordinarie utdelning POLAR 0.00 SEK
2023-03-13 - Extra Bolagsstämma 2022
2023-02-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-27 - Kvartalsrapport 2022-Q1
2022-05-06 - X-dag ordinarie utdelning POLAR 0.00 SEK
2022-05-05 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-28 - Kvartalsrapport 2021-Q1
2021-05-06 - X-dag ordinarie utdelning POLAR 0.00 SEK
2021-05-05 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning POLAR 0.00 SEK
2020-06-30 - Årsstämma
2020-05-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2020-02-14 - Extra Bolagsstämma 2020
2019-10-23 - Kvartalsrapport 2019-Q3
2019-07-24 - Kvartalsrapport 2019-Q2
2019-05-07 - Split POLAR 16:1
2019-04-26 - Kvartalsrapport 2019-Q1
2019-03-19 - Årsstämma
2019-02-04 - X-dag ordinarie utdelning POLAR 0.00 SEK
2019-02-01 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2025-03-20 13:01:00

The Med-Tech company PolarCool AB (publ.) has signed an agreement with football club 1. FC Köln, who compete in the second tier of the German Bundesliga. The agreement includes an initial evaluation period, followed by a two-year commercial contract.

This deal represents a significant step into the German football market for PolarCool. The company already has a strong foothold in German ice hockey, with the majority of DEL (Deutsche Eishockey Liga) clubs utilizing PolarCap®.

While head injuries are more prevalent in ice hockey and rugby, football is emerging as an increasingly important market for PolarCool. Although less frequent, head injuries in football still present serious challenges for players and financial implications for clubs. As awareness grows, PolarCool is seeing increased interest from several top European football clubs.

1. FC Köln's Medical Coordinator Christian Osebold comments;

-Actively working on player welfare and health is a top priority for us at 1. FC Köln. The scientific evidence behind PolarCap® is compelling. I now look forward to be able to provide acute treatment for my players in the event of concussions, and with that reducing the risk of long-term absences.

PolarCool's CEO, Erik Andersson comments;

-With our ambition to expand within European football, we are very pleased to begin this collaboration with 1. FC Köln, a prestigious club in German football. Germany is a key market in Europe, along with others such as France and the United Kingdom. We have been particularly successful in ice hockey and rugby in these countries, which has increased interest from football clubs.

The agreement is financially limited but is considered a strategically important breakthrough in the German market.